Kryptocur (Gonadorelin Acetate)

Gonadorelin acetate mimics natural GnRH by binding to GnRH receptors on the anterior pituitary. This binding triggers a rapid surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), which in turn activate the gonads to produce sex steroids and gametes.

The dosing regimen for Kryptocur is individualized. A qualified prescriber determines the exact dose, frequency, and duration based on the specific diagnostic or therapeutic indication and the patient’s clinical profile.

Safety data for gonadorelin acetate in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a healthcare professional.

To request Kryptocur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Kryptocur delivers gonadorelin acetate via a nasal spray, offering a non‑injectable route that can be more convenient than injectable GnRH analogs. Its rapid onset and short duration make it suitable for diagnostic testing, whereas longer‑acting injectable formulations are often preferred for sustained therapeutic protocols.

Kryptocur should be stored at ambient temperature, preferably below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the nozzle is capped when not in use to maintain product integrity.

Kryptocur is administered as a nasal spray. The prescriber instructs the patient on the number of sprays per nostril and the timing relative to the diagnostic or therapeutic protocol. Proper technique includes tilting the head slightly forward and inhaling gently after each spray.

Serious adverse events, although rare, can include severe allergic reactions such as anaphylaxis, pituitary apoplexy, significant hyponatremia, cardiac arrhythmias, and profound hypotension. Patients should be monitored for any sudden or severe symptoms and seek immediate medical attention if they occur.

Kryptocur is contraindicated in individuals with known hypersensitivity to gonadorelin acetate or any component of the formulation. It should also be avoided in patients with uncontrolled cardiovascular disease, severe pituitary disorders, or when concurrent use of GnRH antagonists would negate its intended effect.